Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2558905 | 0.90 | ESR2 (0.35) | CYP11B2KDM4EL3MBTL1GAA | |
| SCHEMBL287483 | 0.81 | ESR2 (0.34) | — | |
| SCHEMBL664740 | 0.76 | SMN1; SMN2 (0.34) | — | |
| SCHEMBL486771 | 0.76 | ESR2 (0.32) | — | |
| SCHEMBL25346855 | 0.75 | — | — | |
| SCHEMBL294945 | 0.74 | — | — | |
| SCHEMBL19839337 | 0.74 | — | — | |
| SCHEMBL1177140 | 0.74 | SMN1; SMN2 (0.33) | — | |
| SCHEMBL3733449 | 0.72 | KDM4E (0.33) | KDM4EL3MBTL1LMNACYP2C9 | |
| SCHEMBL7366794 | 0.70 | NEK2 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3475262-B1 | BICYCLIC IMIDAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF RENAL DISEASE, CARDIOVASCULAR DISEASES AND FIBROTIC DISORDERS | BOEHRINGER INGELHEIM INT (DE) | 2021-03-24 | — | — | EP | disclosed |
| EP-3475262-B1 | BICYCLIC IMIDAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF RENAL DISEASE, CARDIOVASCULAR DISEASES AND FIBROTIC DISORDERS | BOEHRINGER INGELHEIM INT (DE) | 2021-03-24 | — | — | EP | disclosed |
| US-10858342-B2 | Bicyclic imidazole derivatives useful for the treatment of renal diseases, cardiovascular diseases and fibrotic diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-12-08 | — | — | US | disclosed |
| US-10858342-B2 | Bicyclic imidazole derivatives useful for the treatment of renal diseases, cardiovascular diseases and fibrotic diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-12-08 | — | — | US | disclosed |
| US-20200123127-A1 | REMOVAL OF SENESCENCE-ASSOCIATED MACROPHAGES | EVERON BIOSCIENCES, INC. | 2020-04-23 | — | — | US | disclosed |
| US-20200123127-A1 | REMOVAL OF SENESCENCE-ASSOCIATED MACROPHAGES | EVERON BIOSCIENCES, INC. | 2020-04-23 | — | — | US | disclosed |
| US-20200109131-A1 | BICYCLIC IMIDAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF RENAL DISEASES, CARDIOVASCULAR DISEASES AND FIBROTIC DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-04-09 | — | — | US | disclosed |
| US-RE47493-E1 | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-07-09 | — | — | US | disclosed |
| EP-2935230-B1 | HERBICIDALLY ACTIVE CYCLIC DIONE COMPOUNDS, OR DERIVATIVES THEREOF, SUBSTITUTED BY A PHENYL WHICH HAS AN ALKYNYL-CONTAINING SUBSTITUENT | SYNGENTA LTD (GB) | 2018-01-17 | — | — | EP | disclosed |
| WO-2017189553-A1 | REMOVAL OF SENESCENCE-ASSOCIATED MACROPHAGES | EVERON BIOSCIENCES, INC. (US) | 2017-11-02 | — | — | WO | disclosed |
| WO-2014135414-A1 | SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-09-12 | — | — | WO | disclosed |
| US-20140249129-A1 | Substituted Bicyclic Dihydropyrimidinones And Their Use As Inhibitors Of Neutrophil Elastase Activity | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-09-04 | — | — | US | disclosed |
| WO-2014096289-A2 | HERBICIDALLY ACTIVE CYCLIC DIONE COMPOUNDS, OR DERIVATIVES THEREOF, SUBSTITUTED BY A PHENYL WHICH HAS AN ALKYNYL-CONTAINING SUBSTITUENT | SYNGENTA LIMITED (GB) | 2014-06-26 | — | — | WO | disclosed |
| US-20120021907-A1 | NOVEL HERBICIDES | SYNGENTA CROP PROTECTION LLC (US) | 2012-01-26 | — | — | US | disclosed |
| US-8084649-B2 | Herbicides | SYNGENTA CROP PROTECTION, INC. (US) | 2011-12-27 | — | — | US | disclosed |
| EP-2387569-A1 | NOVEL HERBICIDES | Syngenta Limited (GB) | 2011-11-23 | — | — | EP | disclosed |
| WO-2010081755-A1 | NOVEL HERBICIDES | SYNGENTA LIMITED (GB) | 2010-07-22 | — | — | WO | disclosed |
| US-20100173774-A1 | NOVEL HERBICIDES | SYNGENTA CROP PROTECTION, INC. (US) | 2010-07-08 | — | — | US | disclosed |
| EP-2121584-A2 | NOVEL HERBICIDES | Syngeta Participations AG (CH) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008110308-A2 | NOVEL HERBICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140249129-A1 | Substituted Bicyclic Dihydropyrimidinones And Their Use As Inhibitors Of Neutrophil Elastase Activity | SERPINB1, ELANE, MPO | CYP11B2 1607/4885KDM4E 4052/4885L3MBTL1 4417/4885 |
| US-20200123127-A1 | REMOVAL OF SENESCENCE-ASSOCIATED MACROPHAGES | CD68, CD47, ARG1 | CYP11B2 2506/4885KDM4E 265/4885L3MBTL1 766/4885 |
| US-20120021907-A1 | NOVEL HERBICIDES | DDT, CYP4X1, CYP1B1 | CYP11B2 992/4885KDM4E 1092/4885L3MBTL1 1453/4885 |
| US-20100173774-A1 | NOVEL HERBICIDES | DDT, HDHD5, HPD | CYP11B2 1698/4885KDM4E 756/4885L3MBTL1 1434/4885 |
| US-10858342-B2 | Bicyclic imidazole derivatives useful for the treatment of renal diseases, cardiovascular diseases and fibrotic diseases | REN, AGTR1, AGTR2 | CYP11B2 61/4885KDM4E 1063/4885L3MBTL1 4290/4885 |
| US-20200109131-A1 | BICYCLIC IMIDAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF RENAL DISEASES, CARDIOVASCULAR DISEASES AND FIBROTIC DISEASES | REN, AGTR1, AGTR2 | CYP11B2 61/4885KDM4E 1063/4885L3MBTL1 4290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.